πŸ‡ΊπŸ‡Έ FDA
Patent

US 10662430

RNA interference in ocular indications

granted A61KA61K31/713A61K45/06

Quick answer

US patent 10662430 (RNA interference in ocular indications) held by Phio Pharmaceuticals Corp. expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Phio Pharmaceuticals Corp.
Grant date
Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/713, A61K45/06, A61K47/554, A61K9/0048